A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories

Blood

Volumn 104, Issue 2, 2004, Pages 328-335

  Herling, Marco ^a   Khoury, Joseph D ^a   Washington, LaBaron T ^a   Duvic, Madeleine ^a   Keating, Michael J ^a   Jones, Dan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; BEXAROTENE; CLADRIBINE; COMPOUND 506U; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DENILEUKIN DIFTITOX; FLUDARABINE; GEMCITABINE; GUANINE ARABINOSIDE; IMMUNOGLOBULIN; INTERFERON; ONCOPROTEIN; PENTOSTATIN; PSORALEN; PURINE DERIVATIVE; RETINOID; TCL1 ONCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; BLOOD CELL COUNT; BONE MARROW TRANSPLANTATION; CANCER CLASSIFICATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOPENIA; DISEASE COURSE; EOSINOPHILIA; ERYTHRODERMA; ERYTHRODERMIC SKIN DISEASE; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROLYMPHOCYTE; PROTEIN EXPRESSION; SEZARY SYNDROME; SPLENECTOMY; STEM CELL TRANSPLANTATION; T CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA; T CELL LEUKEMIA; T CELL LYMPHOMA; T CELL PROLYMPHOCYTIC LEUKEMIA; ULTRAVIOLET A RADIATION; WORLD HEALTH ORGANIZATION;

EID: 3142523199     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0002     Document Type: Article

References (33)

1. Jaffe ES, Harris N, Stein H, Vardiman JW. Tumours of Hematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, Lyon, France: IARC Press; 2001.
2. Hoyer JD, Ross CW, Li CY, et al. True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood. 1995;86:1163-1169.
3. Garand R, Goasguen J, Brizard A, et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais d'Hematologie Cellulaire. Br J Haematol. 1998; 103:488-494.
4. Matutes E, Garcia Talavera J, O'Brien M, Catovsky D. The morphological spectrum of T-prolymphocytic leukaemia. Br J Haematol. 1986;64:111-124.
5. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78: 3269-3274.
6. Soulier J, Pierron G, Vecchione D, et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2001;31:248-254.
7. Kojima K, Kobayashi H, Imoto S, et al. 14q11 abnormality and trisomy 8q are not common in Japanese T-cell prolymphocytic leukemia. Int J Hematol. 1998;68:291-296.
8. Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997;89:32-40.
9. Brito-Babapulle V, Maljaie SH, Matutes E, Hedges M, Yuille M, Catovsky D, Relationship of T leukaemias with cerebriform nuclei to T-prolymphocytic leukaemia: a cytogenetic analysis with in situ hybridization. Br J Haematol. 1997;96:724-732.
10. Matutes E, Keeling DM, Newland AC, et al. Sezary cell-like leukemia: a distinct type of mature T cell malignancy [published erratum appears in Leukemia. 1990;4:547]. Leukemia. 1990;4:262-266.
11. Matutes E, Keeling DM, Newland AC, et al. Sezary cell-like leukemia: a distinct type of mature T cell malignancy [published erratum appears in Leukemia. 1990;4:547]. Leukemia. 1990;4:262-266.
12. Vonderheid EC, Bemengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002; 46:95-106.
13. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol. 1995; 131:1003-1008.
14. + large granular lymphocytosis: a new clonal T-cell lymphoproliferative disorder. Am J Pathol. 2003;163:763-771.
15. Macon WR, Levy NB, Kurtin PJ, et al. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol. 2001;25:285-296.
16. Kussick SJ, Wood BL, Sabath DE. Mature T cell leukemias which cannot be adequately classified under the new WHO classification of lymphoid neoplasms. Leukemia. 2002;16:2457-2458.
17. Washington LT, Huh YO, Powers LC, Duvic M, Jones D. A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol. 2002;2: 5-10,
18. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115:885-892.
19. + blastic tumors of skin. Blood. 2003;101:5007-5009.
20. Gandhi V, Plunkett W, Weller S, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001;19:2142-2152.
21. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20:205-213.
22. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol. 2002;3: 193-215.
23. Apisarnthanarax N, Duvic M. Therapy options in cutaneous T-cell lymphoma. Expert Rev Anticancer Ther. 2001;1:403-420.
24. Pekarsky Y, Hallas C, Croce CM. The role of TCL1 in human T-cell leukemia. Oncogene. 2001; 20:5638-5643.
25. Hoyer KK, French SW, Turner DE, et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci U S A. 2002; 99:14392-14397.
26. Virgilio L, Lazzeri C, Bichi R, et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci U S A. 1998;95:3885-3889.
27. Pawson R, Matutes E, Brito-Babapulle V, et al. Sezary cell leukaemia: a distinct T cell disorder or a variant form of T prolymphocytic leukaemia? Leukemia. 1997;11:1009-1013.
28. Serra A, Estrach MT, Marti R, Villamor N, Rafel M, Montserrat E. Cutaneous involvement as the first manifestation in a case of T-cell prolymphocytic leukaemia. Acta Derm Venereol. 1998;78:198-200.
29. Vega F, Medeiros LJ, Bueso-Ramos C, et al. Hepatosplenic gamma/delta T-cell lymphoma in bone marrow: a sinusoidal neoplasm with blastic cytologic features. Am J Clin Pathol. 2001;116: 410-419.
30. Sugimoto T, Imoto S, Matsuo Y, et al. T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype. Ann Hematol. 2001; 80:749-751.
31. Dybjer A, Heliquist L, Johansson B, Rydgren L, Billstrom R. Seropositive polyarthritis and skin manifestations in T-prolymphocytic leukemia/Sezary cell leukemia variant. Leuk Lymphoma. 2000; 37:437-440.
32. Matutes E, Wotherspoon AC, Parker NE, Osuji N, Isaacson PG, Catovsky D. Transformation of T-cell large granular lymphocyte leukaemia into a high-grade large T-cell lymphoma. Br J Haematol. 2001;115:801-806.
33. Jones D, Dorfman DM. Phenotypic characterization of subsets of T cell lymphoma: towards a functional classification of T cell lymphoma. Leuk Lymphoma. 2001;40:449-459.